Well, all I can say to that is...how does he know
Peptide-based strategies for targeted colorectal cancer One of the most frequent types of cancer worldwide is colorectal cancer (CRC)
MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Limited human safety data Animal studies report wide therapeutic window Known interactions Methyl-donor depletion theoretical with chronic dosing (NNMT methylates nicotinamide using SAM) Contraindications Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Not FDA-approved
Sanchez A, Houfaf Khoufaf FZ, Idrissou M, Penault-Llorca F, Bignon YJ, Guy L, Bernard-Gallon D
The sustained and growing body of research on this compound, spanning multiple countries, research institutions, and animal models, reflects a level of reproducibility that supports continued serious investigation
Standard maintenance: - Type I-II: 0.5 mg twice per week - Type III-IV: 0.5 mg once per week - Type V-VI: 0.5 mg every 2-3 weeks Alternative approach: Some users prefer a single larger weekly dose (1.0 mg once per week instead of 0.5 mg twice per week)
.png)
